Abstract
Three frameworks — scientific, public health and legal — are interlinked in the regulation of medicines. How do these frameworks fit together and how are they evolving?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Regnstrom, J. et al. Factors associated with success of marketing authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).
US FDA. Adaptive design clinical trials for drugs and biologics. FDA [online], (2010).
Wise, L. et al. New approaches to drug safety: a pharmacovigilance toolkit. Nature Rev. Drug Discov. 8, 779–782 (2009).
Eichler, H. G. et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Rev. Drug Discov. 7, 818–826 (2008).
Eichler, H. G. et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Rev. Drug Discov. 9, 277–291 (2010).
US FDA. Advancing regulatory science for public health. FDA [online], (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Breckenridge, A., Feldschreiber, P., Gregor, S. et al. Evolution of regulatory frameworks. Nat Rev Drug Discov 10, 3–4 (2011). https://doi.org/10.1038/nrd3348
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3348
This article is cited by
-
Regulatory Review: How Do Agencies Ensure the Quality of Decision Making?
Clinical Pharmacology & Therapeutics (2013)
